Western pharmaceutical companies are in talks with alternative suppliers in response to draft US legislation seeking to restrict an important Chinese drug developer and manufacturer over national security concerns. The Biosecure Act would prohibit US companies receiving federal grant money from working with four Chinese biotech companies, including WuXi AppTec and its sister company WuXi Biologics, which produce active pharmaceutical ingredients (API) for hundreds of US and European drugmakers.
西方制药公司正与替代供应商进行谈判，以应对美国一项立法草案，该草案试图以国家安全为由，限制一家重要的manbetx3.0 药物开发商和制造商。《生物安全法案》(The Biosecure Act)拟禁止接受联邦拨款的美国公司与四家manbetx3.0 生物技术公司合作，其中包括药明康德(WuXi AppTec)及其姊妹公司药明生物(WuXi Biologics)，它们为数百家美国和欧洲制药商生产活性药物成分(API)。
您已阅读10%（692字），剩余90%（6416字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。